DC12438 |
G6PD activator AG1
Featured
|
G6PD activator AG1 (AG1) is a specific, small molecule that increases the activity of the wild-type, Canton mutant (R459L, EC50=3 uM) and several other common G6PD mutants; displays no effect on the dimerization or activity of several other NAD- or NADP+-dependent dimeric or tetrameric enzymes, including 6PGD, GAPDH, ALDH2, and ALDH3A1; attenuates ROS-induced pericardial edema in a G6PD-dependent manner in zebrafish, reduces hemolysis of human erythrocytes |
|
DC21035 |
G907 |
G907 is a potent, selective small-molecule antagonist of ATP-binding cassette (ABC) transporter MsbA with IC50 of 18 nM. |
|
DC21036 |
E-72 |
G9a inhibitor E72 (E-72) is a potent inhibitor of histone H3K9 methyltransferases G9a and G9a-like protein (GLP) with Kd of 136 nM and 164 nM, shows selectivity over the related H3K9 methyltransferase Suv39H2. |
|
DC9129 |
Gabexate mesylate |
Gabexate Mesylate is a Factor X inhibitor. |
|
DCAPI1037 |
Gadodiamide (Omniscan)
Featured
|
Gadodiamide is a gadolinium-based contrast agent used in MR imaging procedures to assist in the visualization of blood vessels. Target: OthersGadodiamide(Omniscan) is a gadolinium-based contrast agent used in MR imaging procedures to assist in the visualization of blood vessels. Gadodiamide is a contrast medium for cranial and spinal magnetic resonance imaging (MRI) and for general MRI of the body after intravenous administration. The product provides contrast enhancement and facilitates visualisation of abnormal structures or lesions in various parts of the body including the central nervous system (CNS). A recent review takes the question of toxicity caused by loss of gadolinium from the complex. "The challenge for nephrologists includes (a) evidence of transmetallation, such as gadolinium deposits in bone, increased urinary zinc excretion, iron-transferrin dissociation or 'spurious hypocalcemia' in exposed people"。 |
|
DC11053 |
GAK inhibitor 49
Featured
|
GAK inhibitor 49 is a potent, selective, ATP-competitive inhibitor of cyclin G-associated kinase (GAK, cell IC50=56 nM) with favourable NAK family selectivity (AAK1, STK16, BMP2K). |
|
DC12228 |
Galactose 1-phosphate |
Galactose 1-phosphate is an intermediate in the galactose metabolism and nucleotide sugars. |
|
DC12305 |
Galactose 1-phosphate Potassium salt |
Galactose 1-phosphate Potassium salt is is an intermediate in the galactose metabolism and nucleotide sugars |
|
DC21038 |
Galvestine-1 |
Galvestine-1 is a small molecule MGDG (monogalactosyldiacylglycerol) synthase inhibitor with IC50 of 10 uM by competing with diacylglycerol binding. |
|
DC12090 |
Gamitrinib TPP |
Gamitrinib TPP is a GA mitochondrial matrix inhibitor. |
|
DC9640 |
gamma-secretase modulator 3 |
gamma-secretase modulator 3 is a gamma-secretase modulator. |
|
DC21197 |
Ganaplacide
Featured
|
Ganaplacide (KAF156, GNF-156) is a novel antimalarial clinical candidate that shows blood schizonticidal activity with IC50 of 6-17.4 nM against P falciparum drug-sensitive and drug-resistant strains. |
|
DCAPI1357 |
Ganciclovir |
Ganciclovir |
|
DC8877 |
Ganirelix
Featured
|
Ganirelix is a man-made form of a protein that reduces the amount of certain hormones in the body, including estrogen. |
|
DC7129 |
GANT61(NSC 136476)
Featured
|
GANT 61(NSC 136476) is a small molecule inhibitor of Gli1 and Gli2. |
|
DC20388 |
GAPDS
Featured
|
GAPDS is a small molecule that targets the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH). |
|
DC23398 |
Garcinol |
Garcinol (Camboginol) is a potent, natural inhibitor of histone acetyltransferases (HATs) p300 (IC50=7 uM) and PCAF (IC50=5 uM) both in vitro and in vivo. |
|
DC22098 |
GB1107 |
GB1107 (GB-1107, GB 1107) is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with Kd of 37 nM (human Galectin-3). |
|
DC21040 |
GB-83 |
GB-83 is a selective, reversible PAR2 (Protease-activated receptor 2) antagonist with IC50 of 2 uM. |
|
DC12671 |
Gboxin
Featured
|
Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma. |
|
DC10474 |
GBT-440(Voxelotor)
Featured
|
GBT-440(Voxelotor) is a novel small molecule hemoglobin modifier which increases hemoglobin oxygen affinity. |
|
DC10896 |
GCN2-IN-1
Featured
|
GCN2-IN-1 is a potent general control nonderepressible 2 kinase (GCN2) inhibitor with IC50s of <0.3 μM in the enzyme and cell assay. |
|
DC7416 |
Taselisib(GDC-0032)
Featured
|
GDC-0032 is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with IC50 of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ. |
|
DC3109 |
Ipatasertib (GDC-0068)
Featured
|
GDC-0068 is a highly selective pan-Akt inhibitor targeting Akt1, Akt2 and Akt3 with IC50 of 5 nM, 18 nM and 8 nM, respectively. |
|
DC8597 |
Gdc-0152
Featured
|
GDC-0152 is a potent inhibitor of IAPs; binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domains of cIAP1 and cIAP2 with K(i) values of 28, 14, 17, and 43 nM, respectively. |
|
DC8216 |
GDC-0349 |
GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM; >700-fold selectivity over PI3Kα and other 266 kinases. |
|
DC8519 |
GDC046
Featured
|
GDC046 is a potent lead analog with good kinase selectivity, physicochemical properties, and pharmacokinetic profile. |
|
DC8000 |
GDC-0623
Featured
|
GDC-0623 is a potent, ATP-uncompetitive inhibitors of MEK1(Ki=0.13 nM, +ATP). |
|
DC23714 |
GDC-0927 R-form |
GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer.. |
|
DC23717 |
GDC-0927 |
GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer.. |
|